Compare stocks

OSE Immunotherapeutics SA is a biotechnology company focused on the research and development of immunotherapies in the fields of immune-oncology, autoimmune diseases, and transplantation. The company aims to innovate through its pipeline, which includes products such as Tedopi, a therapeutic vaccine for non-small cell lung cancer, and CoVepiT, a COVID-19 vaccine. Founded in 2012 and headquartered in Nantes, France, OSE Immunotherapeutics combines strong scientific expertise with a strategic emphasis on building a diversified portfolio of advanced clinical trials. The company's competitive strength lies in its proprietary technologies and strategic partnerships, enhancing its capabilities to address significant unmet medical needs globally.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.